Your browser is no longer supported. Please, upgrade your browser.
Settings
CMRX Chimerix, Inc. daily Stock Chart
CMRX [NASD]
Chimerix, Inc.
Index- P/E- EPS (ttm)-1.55 Insider Own1.20% Shs Outstand47.64M Perf Week-3.54%
Market Cap220.56M Forward P/E- EPS next Y-1.66 Insider Trans-23.96% Shs Float47.11M Perf Month-5.51%
Income-73.10M PEG- EPS next Q-0.44 Inst Own83.50% Short Float1.32% Perf Quarter-6.09%
Sales4.20M P/S52.52 EPS this Y8.50% Inst Trans-0.76% Short Ratio4.12 Perf Half Y2.21%
Book/sh4.32 P/B1.07 EPS next Y6.70% ROA-30.60% Target Price6.40 Perf Year1.31%
Cash/sh3.37 P/C1.38 EPS next 5Y- ROE-32.00% 52W Range4.17 - 5.94 Perf YTD0.00%
Dividend- P/FCF- EPS past 5Y23.40% ROI-33.00% 52W High-22.05% Beta1.25
Dividend %- Quick Ratio18.20 Sales past 5Y-33.20% Gross Margin- 52W Low11.03% ATR0.19
Employees82 Current Ratio18.20 Sales Q/Q-27.30% Oper. Margin- RSI (14)41.58 Volatility4.05% 4.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.20% Profit Margin- Rel Volume1.15 Prev Close4.56
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume150.59K Price4.63
Recom3.10 SMA20-1.79% SMA50-7.10% SMA200-5.07% Volume172,882 Change1.54%
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Feb-23-16Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-23-16Downgrade Barclays Overweight → Equal Weight $12 → $6
Feb-22-16Downgrade Citigroup Buy → Neutral
Dec-29-15Downgrade JP Morgan Overweight → Neutral $65 → $15
Dec-28-15Reiterated Piper Jaffray Overweight $63 → $10
Dec-28-15Downgrade FBR Capital Outperform → Mkt Perform $73 → $14
Dec-17-15Initiated UBS Buy $55
Oct-05-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-03-15Initiated Citigroup Buy
Aug-18-15Initiated FBR Capital Outperform $73
Aug-06-15Reiterated Brean Capital Buy $50 → $57
May-11-15Reiterated Brean Capital Buy $45 → $50
Mar-04-15Initiated Barclays Overweight $55
Feb-12-15Reiterated Stifel Buy $47 → $57
Dec-31-14Reiterated Brean Capital Buy $33 → $45
Jul-08-14Resumed Brean Capital Buy $33
May-17-18 08:20AM  Recent Analysis Shows Camden Property Trust, Biglari, Argan, Chimerix, Workhorse Group, and Magellan Midstream Partners Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
May-10-18 01:45AM  Edited Transcript of CMRX earnings conference call or presentation 7-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-07-18 10:27AM  Want To Invest In Chimerix Inc (NASDAQ:CMRX)? Heres How It Performed Lately Simply Wall St.
07:29AM  Chimerix: 1Q Earnings Snapshot Associated Press
07:00AM  Chimerix Announces First Quarter 2018 Financial Results GlobeNewswire
06:30AM  Chimerix, Inc. to Host Earnings Call ACCESSWIRE
May-02-18 08:00AM  Chimerix to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
Apr-30-18 08:00AM  Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018 GlobeNewswire -7.47%
Apr-02-18 08:00AM  Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire -6.92%
Mar-30-18 03:11PM  Look what Triangle woman just became chairwoman of a $250M company American City Business Journals
Mar-29-18 04:30PM  Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors GlobeNewswire
Mar-23-18 08:48AM  Durham pharma pushing to fight a common cold virus that's deadly to some patients American City Business Journals
Mar-19-18 07:00AM  The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk GlobeNewswire
Mar-07-18 08:00AM  Chimerix to Present at Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-06-18 09:47AM  Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed Zacks
Mar-02-18 07:35AM  New Research: Key Drivers of Growth for Corcept Therapeutics, HubSpot, Tableau Software, Balchem, Steelcase, and Chimerix Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-01-18 08:16PM  Edited Transcript of CMRX earnings conference call or presentation 1-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
08:13AM  Chimerix reports 4Q loss Associated Press
07:00AM  Chimerix Announces Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
06:55AM  Chimerix, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-18 08:00AM  Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018 GlobeNewswire
Feb-15-18 07:39AM  Could These 2 Biotech Stocks Really Double Your Money? Motley Fool
Jan-08-18 07:00AM  Wired News Chimerix Announced Initiation of AdAPT Study for Oral Brincidofovir and Advancement of IV Brincidofovir to Phase-2 Studies ACCESSWIRE
Jan-05-18 08:20AM  Recent Analysis Shows Chimerix, Highwoods Properties, HubSpot, Biglari, IDEXX Laboratories, and Argan Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
07:00AM  Chimerix Initiates AdAPT Study for Oral Brincidofovir and Advances IV Brincidofovir to Patient Studies GlobeNewswire
Jan-03-18 04:01PM  Chimerix to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:57AM  ETFs with exposure to Chimerix, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:54AM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Nov-14-17 05:28AM  Edited Transcript of CMRX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-08-17 09:39AM  Should You Buy Chimerix Inc (CMRX)? Simply Wall St.
07:23AM  Chimerix reports 3Q loss Associated Press
07:00AM  Chimerix Announces Third Quarter 2017 Financial Results GlobeNewswire
06:40AM  Chimerix, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 08:00AM  Chimerix to Present at the Stifel 2017 Healthcare Conference GlobeNewswire
Nov-01-17 08:00AM  Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017 GlobeNewswire
Oct-11-17 11:20AM  ETFs with exposure to Chimerix, Inc. : October 11, 2017 Capital Cube
Sep-27-17 02:25PM  Edited Transcript of CMRX earnings conference call or presentation 7-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Sep-20-17 08:00AM  Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-17 07:00AM  Chimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory Affairs GlobeNewswire
Aug-31-17 05:48PM  ETFs with exposure to Chimerix, Inc. : August 31, 2017 Capital Cube
Aug-24-17 11:23AM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-12-17 07:50AM  Edited Transcript of CMRX earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 09:55AM  Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down Zacks -6.11%
Aug-07-17 11:55PM  Chimerix reports 2Q loss Associated Press
07:00AM  Chimerix Announces Second Quarter 2017 Financial Results GlobeNewswire
06:45AM  Investor Network: Chimerix, Inc. to Host Earnings Call ACCESSWIRE
Jul-31-17 08:30AM  Chimerix to Announce Second Quarter 2017 Financial Results on August 7, 2017 GlobeNewswire
Jun-27-17 03:04PM  ETFs with exposure to Chimerix, Inc. : June 27, 2017 Capital Cube
Jun-05-17 02:09PM  ETFs with exposure to Chimerix, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:53AM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-10-17 08:15AM  Chimerix outlines plans for DNA virus drug American City Business Journals
May-09-17 08:45AM  Chimerix reports 1Q loss Associated Press -6.86%
08:00AM  Investor Network: Chimerix, Inc. to Host Earnings Call Accesswire
07:00AM  Chimerix Announces First Quarter 2017 Financial Results GlobeNewswire
May-02-17 08:00AM  Chimerix to Announce First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire -11.01%
Apr-24-17 02:21PM  ETFs with exposure to Chimerix, Inc. : April 24, 2017 Capital Cube
Apr-20-17 08:00AM  Chimerix to Host Annual Investor Update on April 27, 2017 GlobeNewswire
Apr-18-17 01:00PM  Medical Device Stocks to Beat Estimates this Earnings Season Zacks
Apr-07-17 04:11PM  ETFs with exposure to Chimerix, Inc. : April 7, 2017 Capital Cube
Mar-27-17 03:53PM  ETFs with exposure to Chimerix, Inc. : March 27, 2017 Capital Cube
03:53PM  ETFs with exposure to Chimerix, Inc. : March 27, 2017
Mar-20-17 12:02PM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
12:02PM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-14-17 02:56PM  Chimerix, Inc. :CMRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:56PM  Chimerix, Inc. :CMRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-08-17 01:04PM  CHIMERIX INC Financials
Mar-02-17 05:16PM  Edited Transcript of CMRX earnings conference call or presentation 2-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
08:01AM  CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:29AM  Chimerix reports 4Q loss Associated Press
07:07AM  Q4 2016 Chimerix Inc Earnings Release - Before Market Open
07:00AM  Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 08:00AM  Chimerix to Present at Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-27-17 08:30AM  Universal Health (UHS) Q4 Earnings: What's in the Cards? Zacks
Feb-23-17 08:00AM  Chimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 GlobeNewswire
Feb-22-17 08:00AM  Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings GlobeNewswire
Feb-10-17 08:49AM  5 Breakout Stocks for Superior Returns
Jan-24-17 07:11AM  Will Chimerix (CMRX) Continue to Surge Higher? -7.22%
Jan-13-17 08:51AM  Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
Jan-06-17 08:02AM  CHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects GlobeNewswire
Jan-05-17 04:01PM  Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer GlobeNewswire
Jan-04-17 08:00AM  Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire +6.83%
Dec-09-16 01:06PM  Should You Buy Beigene Ltd (ADR) (BGNE)? at Insider Monkey
Dec-08-16 10:26AM  Here is What Hedge Funds Think About Chimerix Inc (CMRX) at Insider Monkey
Dec-05-16 11:57AM  ETFs with exposure to Chimerix, Inc. : December 5, 2016
Nov-17-16 08:00AM  Chimerix Presents Data from a Preclinical Study of Intravenous Brincidofovir at AAPS GlobeNewswire +10.02%
Nov-10-16 12:09PM  ETFs with exposure to Chimerix, Inc. : November 10, 2016
Nov-09-16 11:38AM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 +10.98%
08:00AM  Chimerix to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-16 01:14PM  Edited Transcript of CMRX earnings conference call or presentation 7-Nov-16 1:30pm GMT
07:54AM  CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:36AM  Chimerix reports 3Q loss
07:07AM  Q3 2016 Chimerix Inc Earnings Release - Before Market Open
07:00AM  Chimerix Announces Third Quarter 2016 Financial Results GlobeNewswire
Oct-31-16 08:00AM  Chimerix to Announce Third Quarter 2016 Financial Results on November 7, 2016 GlobeNewswire
Oct-27-16 04:01PM  Chimerix Announces Presentation at IDWeek of Detailed 24-Week Results from AdVise Trial of Brincidofovir for the Treatment of Adenovirus Infection in Allogeneic Hematopoietic Cell Transplant Recipients GlobeNewswire
Oct-21-16 09:51AM  ETFs with exposure to Chimerix, Inc. : October 21, 2016
Sep-27-16 09:56AM  ETFs with exposure to Chimerix, Inc. : September 27, 2016
Sep-08-16 10:11AM  ETFs with exposure to Chimerix, Inc. : September 8, 2016
Sep-06-16 08:00AM  Chimerix to Present at the Morgan Stanley Global Healthcare Conference GlobeNewswire +6.28%
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIO ERNESTDirectorMay 18Sale4.8115,00072,143108,167May 21 01:34 PM
MARIO ERNESTDirectorMay 17Sale4.8030,000143,931123,167May 21 01:34 PM
MARIO ERNESTDirectorMay 16Sale4.7930,000143,808153,167May 17 11:51 AM
MARIO ERNESTDirectorMay 15Sale4.6930,000140,808183,167May 16 02:46 PM
MARIO ERNESTDirectorMay 14Sale4.6722,553105,232213,167May 15 03:41 PM
MARIO ERNESTDirectorMay 11Sale4.6130,000138,380235,720May 15 03:41 PM
MARIO ERNESTDirectorMay 10Sale4.602,81512,949265,720May 11 05:25 PM
DEMSKI MARTHA JDirectorMay 09Option Exercise1.574,2256,63319,013May 10 03:20 PM
Berrey M MichellePresident and CEOMay 08Option Exercise4.2611,25047,925325,256May 10 05:34 PM
Berrey M MichellePresident and CEOMar 06Option Exercise4.2610,07142,902311,336Mar 08 04:53 PM
Richardson Linda MChief Commercial OfficerDec 01Sale4.4719,83388,67360,996Dec 05 02:08 PM
Berrey M MichellePresident and CEOJun 21Option Exercise4.2623,47499,999323,947Jun 22 04:21 PM